Arbutus Biopharma (ABUS) Cash & Equivalents (2010 - 2026)
Arbutus Biopharma (ABUS) posted Cash & Equivalents of $23.7 million for Q1 2026, up 31.64% sequentially from $18.0 million in Q4 2025, and down 36.06% YoY from $37.1 million in Q1 2025.
Arbutus Biopharma (ABUS) Cash & Equivalents (2010 - 2026) Analysis & Trends
Arbutus Biopharma has reported Cash & Equivalents for 17 years, with the latest figure at $23.7 million in Q1 2026.
- Quarterly Cash & Equivalents fell 36.06% year-over-year to $23.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.7 million (down 36.06% YoY) and the FY2025 annual result came in at $18.0 million, down 50.43% from the prior year.
- Cash & Equivalents rose to $23.7 million in Q1 2026 per ABUS's latest filing, from $18.0 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $81.3 million in Q1 2022 and troughed at $17.5 million in Q3 2023.
- A 5-year average of $35.7 million and a median of $31.8 million in 2024 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2024: Cash & Equivalents slumped 71.84% in 2022, then jumped 130.86% in 2024.
- Over 5 years, Cash & Equivalents stood at $30.8 million in 2022, then slipped by 14.59% to $26.3 million in 2023, then surged by 38.22% to $36.3 million in 2024, then sank by 50.43% to $18.0 million in 2025, then jumped by 31.64% to $23.7 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $23.7 million, $18.0 million, and $22.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 19.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.17 Mn |
| Mar 31, 2026 | 23.71 Mn |
| Dec 31, 2025 | 18.01 Mn |
| Sep 30, 2025 | 22.41 Mn |
| Jun 30, 2025 | 37.41 Mn |
| Mar 31, 2025 | 37.08 Mn |
| Dec 31, 2024 | 36.33 Mn |
| Sep 30, 2024 | 31.85 Mn |
| Jun 30, 2024 | 62.79 Mn |
| Mar 31, 2024 | 43.10 Mn |
| Dec 31, 2023 | 26.29 Mn |
| Sep 30, 2023 | 17.53 Mn |
| Jun 30, 2023 | 27.20 Mn |
| Mar 31, 2023 | 40.57 Mn |
| Dec 31, 2022 | 30.78 Mn |
| Sep 30, 2022 | 24.00 Mn |
| Jun 30, 2022 | 47.32 Mn |
| Mar 31, 2022 | 81.33 Mn |
| Dec 31, 2021 | 109.28 Mn |
| Sep 30, 2021 | 77.88 Mn |